文献速递生殖医学

个性化剂量促卵泡素δ在宫腔内人工授精中应用的前瞻性概念验证试验

A prospective proof-of-concept trial on the effect of personalized dosages of follitropin delta in intrauterine insemination.
PubMed 文献 · Reprod Biomed Online · 2023-10-11

这项单中心前瞻性开放标签单队列研究纳入106例患者,基于体重和抗苗勒管激素(AMH)浓度制定促卵泡素δ个体化给药方案,最多进行三个宫腔内人工授精(IUI)周期。每周期临床妊娠率为17.9%、14.3%和17.6%,累积临床妊娠率40.6%;258个周期中43个(16.7%)临床妊娠,其中6个多胎妊娠(14.0%),4个活产双胎(占总周期1.6%)。作者认为个体化给药有效且安全,达到研究主要目标。

要点

  • 基于体重和AMH的促卵泡素δ个体化剂量用于IUI,每周期临床妊娠率17.9%、14.3%、17.6%。
  • 累积临床妊娠率40.6%,258个周期中43个(16.7%)临床妊娠。
  • 多胎妊娠6例(占临床妊娠14.0%),4例活产双胎,占总周期1.6%。

核心结论

  • 本研究首次将促卵泡素δ用于IUI刺激,显示个体化给药有效且安全,获得满意的累积妊娠率和可接受的多胎妊娠率,达到研究主要目标。

研究设计与样本

  • 单中心、前瞻性、开放标签、单队列研究,纳入106例患者。
  • 基于体重和抗苗勒管激素(AMH)浓度制定促卵泡素δ个体化给药方案,并根据前一IUI周期的卵巢反应进行调整。
  • 每例参与者最多纳入三个IUI周期。

主要发现

  • 平均年龄34.5 ± 4.5岁,平均体重69.2 ± 11.2 kg,平均AMH 15.7 ± 8.6 pmol/l,平均FSH 6.3 ± 2.6 IU/l,平均窦卵泡计数16.4 ± 8.2。
  • 三个IUI周期中,产生超过三个成熟卵泡的患者百分比分别为1.9%、0%和1.5%。
  • 三个IUI周期中,具有两个或三个成熟卵泡的患者百分比分别为34.0%、36.9%和47.1%。
  • 每IUI周期临床妊娠率分别为17.9%、14.3%和17.6%,累积临床妊娠率为40.6%。
  • 258个周期中43个(16.7%)临床妊娠,其中6个多胎妊娠(14.0%);2个在早孕期自然减胎,4个活产双胎,仅占总周期的1.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: What is the efficacy and safety of individualized follitropin delta dosing for ovarian stimulation in intrauterine insemination (IUI)? DESIGN: This single-centre, prospective, open-label, single-cohort study involving 106 patients established an original dosing regimen based on body weight and anti-Müllerian hormone (AMH) concentrations, with adjustments based on the ovarian response from the previous IUI cycle. Each participant was enrolled in a maximum of three IUI cycles. RESULTS: Mean age was 34.5 ± 4.5 years, mean weight 69.2 ± 11.2 kg, mean AMH 15.7 ± 8.6 pmol/l, mean FSH 6.3 ± 2.6 IU/l and mean antral follicle count 16.4 ± 8.2. The percentage of patients who produced more than three mature follicles was 1.9%, 0% and 1.5%, respectively, for the three IUI cycles. The percentage of patients with two or three mature follicles was 34.0%, 36.9% and 47.1% for the three IUI cycles. The clinical pregnancy rate per IUI cycle was 17.9%, 14.3% and 17.6% for the three cycles, with a cumulative clinical pregnancy rate of 40.6%. Out of 258 cycles, 43 (16.7%) resulted in clinical pregnancy, with six of those resulting in multiple pregnancies (14.0%). Two resulted in spontaneous reduction within the first trimester and four resulted in live twin births, representing only 1.6% of the total cycles. CONCLUSIONS: This study is the first to utilize follitropin delta for stimulation in IUI. It demonstrates that individualized dosing is both effective and safe, resulting in satisfactory cumulative pregnancy rates and an acceptable multiple pregnancy rate, thus achieving the primary objectives of the research.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Minano Masip J, Kadoch E, Hemmings R, et al. A prospective proof-of-concept trial on the effect of personalized dosages of follitropin delta in intrauterine insemination. Reprod Biomed Online. 2023. PMID: 38359732. doi:10.1016/j.rbmo.2023.103603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。